Simon James Harrison

44PUBLICATIONS
202CO-AUTHORS
Haematological tumoursImmunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Sep 07, 2026
Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

|Jul 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

|May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

|Apr 08, 2026
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma.

Hans C Lee, Wouter J Plattel, Simon J Harrison

|Feb 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Mark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey

|Jan 15, 2026
The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy.

Arian Lasocki, Simon J Harrison, Michael Dickinson

Pageof 8

Frequent Collaborators

7 joint publications

Mark R Dowling

6 joint publications

Michael J Dickinson

5 joint publications

Andrew Spencer

5 joint publications

Benjamin W Teh